1
|
Mariniello A, Nasti T, Chang D, Malik S, McManus D, McGuire D, Buchwald Z, Novello S, Sangiolo D, Scagliotti G, Ramalingam S, Ahmed R. 222P Platinum-based chemotherapy attenuates the CD8 T cell proliferative response to concomitant PD-1 blockade. Immuno-Oncology and Technology 2022. [DOI: 10.1016/j.iotech.2022.100333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
2
|
Passiglia F, Righi L, Listì A, Tabbò F, Bironzo P, Reale M, Sini C, Vallone S, Arizio F, Parravicini MP, Mazilu L, Linardou H, Roca E, Buffoni L, Mohorcic K, Barbieri V, Pignataro D, Araujo A, Ares LP, Felip E, Secen N, Comanescu A, Szmytke E, Scagliotti G, Novello S. EP16.03-011 The European Program for ROutine Testing of Patients with Advanced Lung Cancer (EPROPA) 1 Year Activity. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.1072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
3
|
Behera M, Jiang R, Huang Z, Bunn B, Wynes M, Switchenko J, Scagliotti G, Belani C, Ramalingam S. P50.05 Natural History and Real-World Treatment Outcomes for NSCLC Patients with EGFR Exon 20 Insertion Mutation: An IASLC- ASCO CancerLinQ Study. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
4
|
Bironzo P, Jacobs F, Cani M, Reale M, Tabbò F, Olmetto E, Capelletto E, Napoli V, Passiglia F, Listì A, Righi L, Di Maio M, Novello S, Scagliotti G. P59.20 Natural History of KRAS Mutant Non-Small-Cell Lung Cancer in the Immunotherapy Era: A Single-Centre Retrospective Study. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.609] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
5
|
Passiglia F, Tabbò F, Righi L, Bironzo P, Reale M, Listi A, Sini C, Vallone S, Arizio F, Secen N, Paz-Ares L, Felip E, Araújo A, Linardou H, Mohorcic K, Mazilu L, Szmytke E, Comanescu A, Scagliotti G, Novello S. 1368TiP EPROPA: The European program for routine testing of patients with advanced lung cancer. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1969] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
6
|
Saad F, de Bono J, Barthelemy P, Dorff T, Mehra N, Scagliotti G, Stirling A, Machiels JP, Renard V, Maruzzo M, Higano C, Gurney H, Healy C, Bhattacharyya H, Arondekar B, Niyazov A, Fizazi K. 581P Patient (pt) reported pain in men with metastatic castration-resistant prostate cancer (mCRPC) receiving talazoparib (TALA): TALAPRO-1. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
7
|
Novello S, Monica V, Serke M, Grohe C, Meyer A, Geissler M, Colantonio I, Stoelben E, Cecere F, Schutte W, Schumann C, Valmadre G, Borra G, Schena M, Morabito A, Santo A, Chiari R, Gregorc V, Reck M, Manegold C, Griesinger F, Follador A, Ferrari A, Bearz A, Caffo O, Dickgreber N, Irtelli L, Wiest G, Sotoparra H, Spatafora M, Righi L, Torri V, Porcu L, Arizio F, Scagliotti G. PS01.04 International Tailored Chemotherapy Adjuvant Trial : ITACA Trial. Final Results. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.319] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
8
|
Smeltzer M, Wynes M, Lantuejoul S, Soo R, Dalurzo L, Felip E, Hollenbeck G, Howell K, Kerr K, Kim E, Mathias C, Postmus P, Powell C, Ramalingam S, Richeimer K, Taylor M, Tsuboi M, Varella-Garcia M, Wistuba I, Wood K, Scagliotti G, Hirsch F. OA01.09 Comparing Regional Results from the IASLC Global Survey on Molecular Testing in Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.09.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
9
|
Garcia M, Smeltzer M, Wynes M, Lantuejoul S, Soo R, Dalurzo L, Felip E, Howell K, Kerr K, Kim E, Mathias C, Postmus P, Powell C, Ramalingam S, Richeimer K, Taylor M, Tsuboi M, Wistuba I, Wood K, Scagliotti G, Hirsch F. O.04 Results from the IASLC Global Survey on Molecular Testing in Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.09.091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
10
|
Reale M, De Luca E, Lombardi P, Marandino L, Zichi C, Pignataro D, Ghisoni E, Di Stefano R, Mariniello A, Trevisi E, Leone G, Muratori L, La Salvia A, Sonetto C, Bironzo P, Aglietta M, Novello S, Scagliotti G, Perrone F, Di Maio M. OA07.07 Quality of Life (QoL) Analysis in Lung Cancer: A Systematic Review of Phase III Trials Published Between 2012 and 2018. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
11
|
Scagliotti G. YI01.02 Why to Become a Member of the IASLC. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.2488] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
12
|
Passiglia F, Capelletto E, Grossi F, Bidoli P, Galetta D, Follador A, Valmadre G, Defferrari C, Caffo O, Bearz A, Colantonio I, Gregorc V, Scotti V, Cognetti F, Cordero L, Arizio F, Novello S, Torri V, Scagliotti G. The elderly patient individualized chemotherapy (EPIC) trial, a study for an aged population of non-small cell lung cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.110] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
13
|
Lombardi P, Marandino L, De Luca E, Zichi C, Pignataro D, Di Stefano R, Ghisoni E, Mariniello A, Reale M, Trevisi E, Gianmarco L, Muratori L, La Salvia A, Sonetto C, Leone F, Aglietta M, Novello S, Scagliotti G, Perrone F, Di Maio M. Quality of life assessment and reporting in colorectal cancer: a systematic review of phase 3 trials published between 2012 and 2018. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
14
|
Scagliotti G. SP-0209 Multidisciplinary approaches as the keys to defeat lung cancer. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)30629-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
15
|
Dingemans A, Hendriks L, Berghmans T, Levy A, Hasan B, Faivre-Finn C, Giaj Levra M, Giaj-Levra N, Girard N, Greillier L, Lantuejoul S, Edwards J, O'Brien M, Reck M, Smit E, Van Schil P, Postmus P, Ramella S, Lievens Y, Gaga M, Peled N, Scagliotti G, Senan S, Paz-Ares L, Guckenberger M, Mcdonald F, Ekman S, Cufer T, Gietema H, Infante M, Dziadziuszko R, Besse B, Novello S. MA25.02 Searching for a Definition of Synchronous Oligometastatic (sOMD)-NSCLC: A Consensus from Thoracic Oncology Experts. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.530] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
16
|
Scagliotti G, Gaafar R, Nowak A, Tsao A, Vogelzang N, Kuribayashi K, Velema D, Morsli N, Popat S. PS04.03 LUME-Meso Phase II/III Study: Nintedanib + Pemetrexed/Cisplatin in Chemo-Naïve Patients with Malignant Pleural Mesothelioma. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
17
|
Riganti C, Pradotto M, Righi L, Marchiò C, Capelletto E, Buttigliero C, Costardi L, Kopecka J, Bironzo P, Ruffini E, Novello S, Scagliotti G. P2.09-003 Dissecting the Immune Environment in Malignant Pleural Mesothelioma: Results from a Prospective Assessment. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1328] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
18
|
Novello S, Nowak A, Grosso F, Steele N, Popat S, Greillier L, John T, Leighl N, Reck M, Pavlakis N, Sorensen J, Planchard D, Ceresoli G, Hughes B, Mazieres J, Socinski M, Von Wangenheim U, Barrueco J, Morsli N, Scagliotti G. OA03.06 Overall Survival and Forced Vital Capacity in the LUME-Meso Study of Nintedanib + Pemetrexed/Cisplatin in Patients with Mesothelioma. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
19
|
Gandara D, Herbst R, Mok T, Ramalingam S, Obholz K, Quill T, Chow H, Scagliotti G. MA 07.14 Change in Practice Patterns from an Online NSCLC Treatment Decision Support Tool. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
20
|
Nowak A, Grosso F, Steele N, Novello S, Popat S, Greillier L, John T, Leighl N, Reck M, Pavlakis N, Sørensen J, Planchard D, Ceresoli G, Hughes B, Mazieres J, Socinski M, Salnikov A, Kitzing T, Braunger J, Pietzko K, Scagliotti G. MA 19.03 Nintedanib + Pemetrexed/Cisplatin in Malignant Pleural Mesothelioma (MPM): Phase II Biomarker Data from the LUME-Meso Study. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.636] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
21
|
Novello S, Nowak A, Grosso F, Steele N, Popat S, Greillier L, John T, Leighl N, Reck M, Pavlakis N, Sorensen J, Planchard D, Ceresoli G, Hughes B, Mazieres J, Socinski M, von Wangenheim U, Barrueco J, Morsli N, Scagliotti G. Overall survival (OS) and forced vital capacity (FVC) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx389.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
22
|
Popat S, Gaafar R, Nowak A, Tsao A, Van Meerbeeck J, Vogelzang N, Nakano T, Velema D, Morsli N, Scagliotti G. LUME-Meso: Randomised phase II/III study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) followed by maintenance N or placebo (P) in chemo-naïve patients with malignant pleural mesothelioma (MPM). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx093.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
23
|
Mok T, Scagliotti G, Kim T, Crinò L, Liu G, Gridelli C, Novello S, Kiura K, Bearz A, Gautschi O, Felip E, Nishio M, Spigel D, Urban P, Deudon S, Zheng C, Shaw A. 444PD Patient-reported outcomes (PROs) in ASCEND-5: A randomized, phase 3 study of ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase rearranged (ALK+) NSCLC previously treated with CT and crizotinib (CRZ). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw594.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
24
|
Mok T, Scagliotti G, Kim T, Crino L, Liu G, Gridelli C, Novello S, Kiura K, Bearz A, Gautschi O, Felip E, Nishio M, Spigel D, Urban P, Deudon S, Zheng C, Shaw A. 444PD Patient-reported outcomes (PROs) in ASCEND-5: A randomized, phase 3 study of ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase rearranged (ALK +) NSCLC previously treated with CT and crizotinib (CRZ). Ann Oncol 2016. [DOI: 10.1016/s0923-7534(21)00602-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
25
|
von Moos R, Costa L, Scagliotti G, Sleeboom H, Goldwasser F, Hirsh V, Spencer A, Radcliffe HS, Niepel D, Henry D. Symptomatic skeletal events (SSEs) versus skeletal-related events (SREs) in patients with advanced cancer and bone metastases treated with denosumab or zoledronic acid. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw390.33] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
26
|
Sonetto C, Baratelli C, Brizzi M, Di Maio M, Scagliotti G, Tampellini M. Pharmacological bioquivalence of branded and generic oxaliplatin: from preclinical assessment to clinical incidence of hypersensitivity reactions in patients with colorectal cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw370.50] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Felip E, Orlov S, Park K, Yu CJ, Tsai CM, Nishio M, Dols M, McKeage M, Su WC, Mok T, Scagliotti G, Spigel D, Passos V, Chen V, Munarini F, Shaw A. Phase 2 study of ceritinib in ALKi-naïve patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC): Whole body responses in the overall pt group and in pts with baseline brain metastases (BM). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw383.03] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Scagliotti G, Kim T, Crinò L, Liu G, Gridelli C, Novello S, Kiura K, Bearz A, Gautschi O, Felip E, Nishio M, Spigel D, Mok T, Urban P, Deudon S, Zheng C, Shaw A. Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): Results from the confirmatory phase 3 ASCEND-5 study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw435.41] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
29
|
Patel J, Pereira J, Chen J, Liu J, Guba S, John W, Orlando M, Scagliotti G, Bonomi P. Relationship between efficacy outcomes and weight gain during treatment of advanced, non-squamous, non-small-cell lung cancer patients. Ann Oncol 2016; 27:1612-9. [DOI: 10.1093/annonc/mdw211] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2016] [Accepted: 05/11/2016] [Indexed: 01/03/2023] Open
|
30
|
Novello S, Pinto C, Torri V, Porcu L, Di Maio M, Tiseo M, Ceresoli G, Magnani C, Silvestri S, Veltri A, Papotti M, Rossi G, Ricardi U, Trodella L, Rea F, Facciolo F, Granieri A, Zagonel V, Scagliotti G. The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations. Crit Rev Oncol Hematol 2016; 104:9-20. [PMID: 27286698 DOI: 10.1016/j.critrevonc.2016.05.004] [Citation(s) in RCA: 61] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2015] [Revised: 03/17/2016] [Accepted: 05/10/2016] [Indexed: 11/26/2022] Open
Abstract
Malignant Pleural Mesothelioma (MPM) remains a relevant public health issue, and asbestos exposure is the most relevant risk factor. The incidence has considerably and constantly increased over the past two decades in the industrialized countries and is expected to peak in 2020-2025. In Italy, a standardized-rate incidence in 2011 among men was 3.5 and 1.25 per 100,000 in men and women, respectively, and wide differences are noted among different geographic areas. The disease remains challenging in terms of diagnosis, staging and treatment and an optimal strategy has not yet been clearly defined. The Third Italian Multidisciplinary Consensus Conference on Malignant Pleural Mesothelioma was held in Bari (Italy) in January 30-31, 2015. This Consensus has provided updated recommendations on the MPM management for health institutions, clinicians and patients.
Collapse
Affiliation(s)
- S Novello
- Department of Oncology, University of Turin, Italy.
| | - C Pinto
- Medical Oncology Unit, IRCCS-Arciospedale Santa Maria Nuova, Reggio Emilia, Italy
| | - V Torri
- Department of Oncology, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
| | - L Porcu
- Department of Oncology, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
| | - M Di Maio
- Department of Oncology, University of Turin, Italy
| | - M Tiseo
- Division of Medical Oncology, Azienda Ospedaliera Universitaria di Parma, Italy
| | - G Ceresoli
- Thoracic Oncology Unit, Humanitas Gavazzeni, Bergamo, Italy
| | - C Magnani
- Cancer Epidemiology, University of Eastern Piedmont and CPO-Piemonte, Novara, Italy
| | - S Silvestri
- Istituto per lo Studio e la Prevenzione Oncologica, Florence, Italy
| | - A Veltri
- Department of Oncology, University of Turin, Italy
| | - M Papotti
- Department of Oncology, University of Turin, Italy
| | - G Rossi
- Ospedale Policlinico, Division of Human Pathology, Modena, Italy
| | - U Ricardi
- Department of Oncology, University of Turin, Italy
| | - L Trodella
- Department of Radiotherapy, Campus Bio-Medico University, Rome, Italy
| | - F Rea
- Azienda Ospedaliera, Division of Thoracic Surgery, Padua, Italy
| | - F Facciolo
- Regina Elena Cancer Institute, Division of Thoracic Surgery, Rome, Italy
| | - A Granieri
- University of Torino, Department of Psychology, Italy
| | - V Zagonel
- Veneto Oncology Institute, IRCCS Padova, Italy
| | - G Scagliotti
- Department of Oncology, University of Turin, Italy
| |
Collapse
|
31
|
Birocco N, Brizzi M, Airoldi M, De Angelis C, Maletta F, Piovesan A, Rapa I, Sapino A, Scaldaferri M, Scagliotti G, Papotti M, Volante M. Phospho-mTOR expression levels, proliferative acitivity (Ki67) and pancreatic primary tumor may influence the response to everolimus in neuroendocrine tumor patients: results from an Italian preliminary study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv348.26] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
32
|
Pastorino U, Platania M, Rea F, Schiavon M, Ceribelli A, Mussi A, Monica V, Das M, Soldatenkova V, Visseren-Grul C, Scagliotti G. An Exploratory Phase 2 Study of Pemetrexed (Pem) and Cisplatin (Cis) As Preoperative Chemotherapy (Ct) in the Treatment of Stage Iiian2 Nonsquamous Non-Small Cell Lung Cancer (Ns Nsclc). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu348.9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
33
|
Tariq N, Bertaglia V, Shah N, Mele T, Alamgir R, Khan N, Summers Y, Taylor P, Harris M, Bayman N, Sheikh H, Chittalia A, Pemberton L, Lee L, Coote J, Faivre-Finn C, Scagliotti G, Blackhall F, Novello S, Califano R. Outcomes of Elderly Patients (≥70 Yo) with Advanced Non-Small Cell Lung Cancer (Nsclc): a Multi-Institutional Analysis. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.39] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
34
|
Shaw A, Tan D, Crinò L, Felip E, Mok T, Nishio M, Paz-Ares L, Scagliotti G, Spigel D, Wolf J, Wu Y, Castro G, Sen P, Zheng C, Joe A, Soria JC. Two Phase III Studies Evaluating Ceritinib in Patients (Pts) with Anaplastic Lymphoma Kinase (Alk)-Rearranged (Alk+) Non-Small Cell Lung Cancer (Nsclc): Ascend-4 and Ascend-5. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.111] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
35
|
Vavala T, Novello S, Grossi F, Misino A, Cortinovis D, Valmadre G, Meoni G, Caffo O, Follador A, Bearz A, Trenta P, Gregorc V, Defferrari C, Cordero L, Colantonio I, Torri V, Monica V, Papotti M, Scagliotti G. A Randomized Phase III Multicenter Trial of Customized Chemotherapy Versus Standard of Care for 1St Line Treatment of Elderly Patients with Advanced Non-Small-Cell Lung Cancer (Nsclc): the Elderly Patient Individualized Chemotherapy (Epic) Trial. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
36
|
Novello S, Besse B, Felip E, Barlesi F, Mazieres J, Zalcman G, von Pawel J, Reck M, Cappuzzo F, Ferry D, Carcereny E, Santoro A, Garcia-Ribas I, Scagliotti G, Soria JC. A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer. Ann Oncol 2014; 25:2156-2162. [PMID: 25139550 DOI: 10.1093/annonc/mdu384] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Iniparib is a novel anticancer agent initially considered a poly (ADP-ribose) polymerase (PARP) inhibitor, but subsequently shown to act via non-selective protein modification through cysteine adducts. This randomized phase II study investigated the addition of iniparib to gemcitabine-cisplatin in metastatic non-small-cell lung cancer (NSCLC) patients. PATIENTS AND METHODS Patients with histologically confirmed stage IV NSCLC were randomized 2 : 1 to receive gemcitabine (1250 mg/m(2), days 1/8) and cisplatin (75 mg/m(2), day 1) with [gemcitabine/cisplatin/iniparib (GCI)] or without [gemcitabine/cisplatin (GC)] iniparib (5.6 mg/kg, days 1/4/8/11) every 3 weeks for six cycles. The primary end point was the overall response rate (ORR). Secondary objectives included progression-free survival (PFS), overall survival (OS), and safety. The study was not designed for formal efficacy comparison, the control arm being to benchmark results against the literature. RESULTS One hundred and nineteen patients were randomized (39 GC and 80 GCI). More GCI patients were male (80% GCI and 67% GC) and had PS 0 (61% GCI and 49% GC). The ORR was 25.6% [95% confidence interval (CI) 13.0%-42.1%] with GC versus 20.0% (95% CI 11.9%-30.4%) with GCI, which did not allow rejection of the null hypothesis (ORR with GCI ≤20%; P = 0.545). Median PFS was 4.3 (95% CI 2.8-5.6) months with GC and 5.7 (95% CI 4.6-6.6) months with GCI (hazard ratio 0.89, 95% CI 0.56-1.40). Median OS was 8.5 (95% CI 5.5 to not reached) months with GC, and 12.0 (95% CI 8.9-17.1) months with GCI (hazard ratio 0.78, 95% CI 0.48-1.27). More GCI patients received second-line treatment (51% GC and 68% GCI). Toxicity was similar in the two arms. Grade 3-4 toxicities included asthenia (28% GC and 8% GCI), nausea (3% GC and 14% GCI), and decreased appetite (10% in each). CONCLUSIONS Addition of iniparib to GC did not improve ORR over GC alone. The GCI safety profile was comparable to GC alone. Imbalances in PS and gender distribution may have impacted study results regarding PFS and OS. TRIAL REGISTRATION ClinicalTrial.gov Identifier NCT01086254.
Collapse
Affiliation(s)
- S Novello
- Department of Oncology, University of Turin, AOU San Luigi, Orbassano, Italy
| | - B Besse
- Thoracic Cancer Unit, Department of Medicine, Gustave-Roussy, Villejuif, France.
| | - E Felip
- Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - F Barlesi
- Multidisciplinary Oncology and Therapeutic Innovations Department, Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille
| | - J Mazieres
- Department of Pneumology and Allergies, CHU Toulouse Hôpital Larrey, Toulouse
| | - G Zalcman
- Department of Pneumology, CHU Côte de Nacre, Caen, France
| | - J von Pawel
- Department of Oncology, Asklepios Fachkliniken München-Gauting, Gauting
| | - M Reck
- Thoracic Oncology, LungenClinic Grosshansdorf, Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany
| | - F Cappuzzo
- Department of Medical Oncology, Istituto Toscano Tumori-Ospedale Civile, Livorno, Italy
| | - D Ferry
- Department of Oncology, New Cross Hospital, Wolverhampton, UK
| | - E Carcereny
- Department of Medical Oncology, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain
| | - A Santoro
- Department of Medical Oncology, Humanitas Cancer Center IRCCS, Milan, Italy
| | | | - G Scagliotti
- Department of Oncology, University of Turin, AOU San Luigi, Orbassano, Italy
| | - J-C Soria
- Thoracic Cancer Unit, Department of Medicine, Gustave-Roussy, Villejuif, France
| |
Collapse
|
37
|
Pawel JV, Scagliotti G, Novello S, Ramlau R, Favaretto A, Barlesi F, Akerley W, Orlov S, Santoro A, Shepherd F, Spigel D, Hirsh V, Sequist L, Shuster D, Zahir H, Wang Q, Schwartz B, Roemeling RV, Sandler AB. Efficacy Analysis for Molecular Subgroups in MARQUEE: a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial of Tivantinib (ARQ 197) Plus Erlotinib versus Placebo plus Erlotinib in Previously Treated Patients with Locally Advanced or Metastatic, Non-squamous, Non-small Cell Lung Cancer (NSCLC). Pneumologie 2014. [DOI: 10.1055/s-0034-1367776] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
38
|
Kubota K, Ichinose Y, Scagliotti G, Spigel D, Kim JH, Shinkai T, Takeda K, Kim SW, Hsia TC, Li RK, Tiangco BJ, Yau S, Lim WT, Yao B, Hei YJ, Park K. Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis. Ann Oncol 2014; 25:529-36. [PMID: 24419239 DOI: 10.1093/annonc/mdt552] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND This preplanned subset analysis of the phase III MONET1 study aimed to determine whether motesanib combined with carboplatin/paclitaxel (C/P) would result in improved overall survival (OS) versus chemotherapy alone, in a subset of Asian patients with nonsquamous nonsmall-cell lung cancer (NSCLC). PATIENTS AND METHODS Patients with nonsquamous NSCLC (stage IIIB/IV or recurrent) and no prior systemic therapy for advanced disease were randomized to IV carboplatin (AUC, 6 mg/ml min) and paclitaxel (200 mg/m2) for up to six 3-week cycles, plus either oral motesanib 125 mg q.d. or placebo. Primary end point was OS; secondary end points included progression-free survival (PFS), objective response rate (ORR), and safety. RESULTS Two hundred twenty-seven Asian patients from MONET1 were included in this descriptive analysis. Median OS was 20.9 months in the motesanib plus C/P arm and 14.5 months in the placebo plus C/P arm (P=0.0223); median PFS was 7.0 and 5.3 months, respectively, (P=0.0004); and ORR was 62% and 27%, respectively, (P<0.0001). Grade≥3 adverse events were more common in the motesanib plus C/P arm versus placebo plus C/P (79% versus 61%). CONCLUSION In this preplanned subset analysis of Asian patients with nonsquamous NSCLC, motesanib plus C/P significantly improved OS, PFS, and ORR versus placebo plus C/P. CLINICAL TRIAL NUMBER NCT00460317.
Collapse
Affiliation(s)
- K Kubota
- Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Scagliotti G, Kim D, Shaw A, Ou S, Riely G, Gettinger S, Besse B, Wilner K, Tang Y, Bartlett C. A Large Retrospective Analysis of Pemetrexed (PEM) Activity in Patients (PTS) with Alk-Positive (Alk+) Non-Small Cell Lung Cancer (NSCLC) Prior to Crizotinib (CRIZ) Treatment. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33862-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
40
|
Scagliotti G, Vynnychenko I, Ichinose Y, Park K, Kubota K, Blackhall FH, Pirker R, Galiulin R, Ciuleanu T, Sydorenko O, Dediu M, Papai-Szekely Z, Martinez Banaclocha N, McCoy S, Yao B, Hei YJ, Spigel DR. An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.18_suppl.lba7512] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
LBA7512 Background: This study evaluated whether motesanib (a selective oral inhibitor of VEGFR 1, 2 and 3; PDGFR and Kit) plus C/P improved overall survival (OS) compared with placebo + C/P in patients (pts) with nonsquamous NSCLC and in a subset of pts with adenocarcinoma. Methods: Pts had stage IIIB/IV or recurrent nonsquamous NSCLC and no prior systemic therapy for advanced NSCLC. The study initially enrolled all histologies but was amended to exclude pts with squamous NSCLC owing to a high rate of hemoptysis. Pts were randomized 1:1 to receive up to six 3-wk cycles of C (AUC 6 mg/mL·min) and P (200 mg/m2) with either motesanib 125 mg QD (Arm A) or placebo QD (Arm B) orally continuously. The primary endpoint was OS; secondary endpoints included progression-free survival (PFS), adverse events (AEs), objective response rate (ORR) and association between placental growth factor (PLGF) change and OS. OS was evaluated using a stratified Cox model and 2-sided log-rank test (α=0.03 for nonsquamous pts and α=0.02 for adenocarcinoma pts). Results: 1090 pts with nonsquamous NSCLC were randomized (Arm A/B, n=541/549); 890 had adenocarcinoma (n=448/442). 61% were men; median age was 60 years (range 21–87); 83% had stage IV disease. At the time of analysis, 753 pts had died (608 pts with adenocarcinoma). Median follow-up was 10.6 mo. OS was not significantly improved in Arm A compared with Arm B (Table). In Arm A, PLGF analysis did not show an association with OS. The incidence of grade ≥3 AEs in Arms A/B was 73/59%. Grade ≥3 AEs occurring more frequently in Arm A than B included neutropenia (22/15%), diarrhea (9/1%), hypertension (7/1%) and cholecystitis (3/0%). The incidence of grade 5 AEs was 14/9% in Arms A/B. Conclusions: In pts with advanced nonsquamous NSCLC, treatment with motesanib + C/P did not significantly improve OS compared with C/P alone. [Table: see text]
Collapse
Affiliation(s)
- G. Scagliotti
- Department of Clinical and Biological Sciences, University of Turin, S. Luigi Hospital, Turin, Italy; Sumy Regional Oncology Centre, Sumy, Ukraine; National Kyushu Cancer Center, Fukuoka, Japan; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; National Cancer Center, Tokyo, Japan; Department of Medical Oncology, The Christie National Health Services Foundation Trust, Manchester, United Kingdom; Department of Medicine I, Medical University Vienna, Vienna, Austria
| | - I. Vynnychenko
- Department of Clinical and Biological Sciences, University of Turin, S. Luigi Hospital, Turin, Italy; Sumy Regional Oncology Centre, Sumy, Ukraine; National Kyushu Cancer Center, Fukuoka, Japan; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; National Cancer Center, Tokyo, Japan; Department of Medical Oncology, The Christie National Health Services Foundation Trust, Manchester, United Kingdom; Department of Medicine I, Medical University Vienna, Vienna, Austria
| | - Y. Ichinose
- Department of Clinical and Biological Sciences, University of Turin, S. Luigi Hospital, Turin, Italy; Sumy Regional Oncology Centre, Sumy, Ukraine; National Kyushu Cancer Center, Fukuoka, Japan; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; National Cancer Center, Tokyo, Japan; Department of Medical Oncology, The Christie National Health Services Foundation Trust, Manchester, United Kingdom; Department of Medicine I, Medical University Vienna, Vienna, Austria
| | - K. Park
- Department of Clinical and Biological Sciences, University of Turin, S. Luigi Hospital, Turin, Italy; Sumy Regional Oncology Centre, Sumy, Ukraine; National Kyushu Cancer Center, Fukuoka, Japan; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; National Cancer Center, Tokyo, Japan; Department of Medical Oncology, The Christie National Health Services Foundation Trust, Manchester, United Kingdom; Department of Medicine I, Medical University Vienna, Vienna, Austria
| | - K. Kubota
- Department of Clinical and Biological Sciences, University of Turin, S. Luigi Hospital, Turin, Italy; Sumy Regional Oncology Centre, Sumy, Ukraine; National Kyushu Cancer Center, Fukuoka, Japan; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; National Cancer Center, Tokyo, Japan; Department of Medical Oncology, The Christie National Health Services Foundation Trust, Manchester, United Kingdom; Department of Medicine I, Medical University Vienna, Vienna, Austria
| | - F. H. Blackhall
- Department of Clinical and Biological Sciences, University of Turin, S. Luigi Hospital, Turin, Italy; Sumy Regional Oncology Centre, Sumy, Ukraine; National Kyushu Cancer Center, Fukuoka, Japan; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; National Cancer Center, Tokyo, Japan; Department of Medical Oncology, The Christie National Health Services Foundation Trust, Manchester, United Kingdom; Department of Medicine I, Medical University Vienna, Vienna, Austria
| | - R. Pirker
- Department of Clinical and Biological Sciences, University of Turin, S. Luigi Hospital, Turin, Italy; Sumy Regional Oncology Centre, Sumy, Ukraine; National Kyushu Cancer Center, Fukuoka, Japan; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; National Cancer Center, Tokyo, Japan; Department of Medical Oncology, The Christie National Health Services Foundation Trust, Manchester, United Kingdom; Department of Medicine I, Medical University Vienna, Vienna, Austria
| | - R. Galiulin
- Department of Clinical and Biological Sciences, University of Turin, S. Luigi Hospital, Turin, Italy; Sumy Regional Oncology Centre, Sumy, Ukraine; National Kyushu Cancer Center, Fukuoka, Japan; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; National Cancer Center, Tokyo, Japan; Department of Medical Oncology, The Christie National Health Services Foundation Trust, Manchester, United Kingdom; Department of Medicine I, Medical University Vienna, Vienna, Austria
| | - T. Ciuleanu
- Department of Clinical and Biological Sciences, University of Turin, S. Luigi Hospital, Turin, Italy; Sumy Regional Oncology Centre, Sumy, Ukraine; National Kyushu Cancer Center, Fukuoka, Japan; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; National Cancer Center, Tokyo, Japan; Department of Medical Oncology, The Christie National Health Services Foundation Trust, Manchester, United Kingdom; Department of Medicine I, Medical University Vienna, Vienna, Austria
| | - O. Sydorenko
- Department of Clinical and Biological Sciences, University of Turin, S. Luigi Hospital, Turin, Italy; Sumy Regional Oncology Centre, Sumy, Ukraine; National Kyushu Cancer Center, Fukuoka, Japan; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; National Cancer Center, Tokyo, Japan; Department of Medical Oncology, The Christie National Health Services Foundation Trust, Manchester, United Kingdom; Department of Medicine I, Medical University Vienna, Vienna, Austria
| | - M. Dediu
- Department of Clinical and Biological Sciences, University of Turin, S. Luigi Hospital, Turin, Italy; Sumy Regional Oncology Centre, Sumy, Ukraine; National Kyushu Cancer Center, Fukuoka, Japan; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; National Cancer Center, Tokyo, Japan; Department of Medical Oncology, The Christie National Health Services Foundation Trust, Manchester, United Kingdom; Department of Medicine I, Medical University Vienna, Vienna, Austria
| | - Z. Papai-Szekely
- Department of Clinical and Biological Sciences, University of Turin, S. Luigi Hospital, Turin, Italy; Sumy Regional Oncology Centre, Sumy, Ukraine; National Kyushu Cancer Center, Fukuoka, Japan; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; National Cancer Center, Tokyo, Japan; Department of Medical Oncology, The Christie National Health Services Foundation Trust, Manchester, United Kingdom; Department of Medicine I, Medical University Vienna, Vienna, Austria
| | - N. Martinez Banaclocha
- Department of Clinical and Biological Sciences, University of Turin, S. Luigi Hospital, Turin, Italy; Sumy Regional Oncology Centre, Sumy, Ukraine; National Kyushu Cancer Center, Fukuoka, Japan; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; National Cancer Center, Tokyo, Japan; Department of Medical Oncology, The Christie National Health Services Foundation Trust, Manchester, United Kingdom; Department of Medicine I, Medical University Vienna, Vienna, Austria
| | - S. McCoy
- Department of Clinical and Biological Sciences, University of Turin, S. Luigi Hospital, Turin, Italy; Sumy Regional Oncology Centre, Sumy, Ukraine; National Kyushu Cancer Center, Fukuoka, Japan; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; National Cancer Center, Tokyo, Japan; Department of Medical Oncology, The Christie National Health Services Foundation Trust, Manchester, United Kingdom; Department of Medicine I, Medical University Vienna, Vienna, Austria
| | - B. Yao
- Department of Clinical and Biological Sciences, University of Turin, S. Luigi Hospital, Turin, Italy; Sumy Regional Oncology Centre, Sumy, Ukraine; National Kyushu Cancer Center, Fukuoka, Japan; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; National Cancer Center, Tokyo, Japan; Department of Medical Oncology, The Christie National Health Services Foundation Trust, Manchester, United Kingdom; Department of Medicine I, Medical University Vienna, Vienna, Austria
| | - Y. J. Hei
- Department of Clinical and Biological Sciences, University of Turin, S. Luigi Hospital, Turin, Italy; Sumy Regional Oncology Centre, Sumy, Ukraine; National Kyushu Cancer Center, Fukuoka, Japan; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; National Cancer Center, Tokyo, Japan; Department of Medical Oncology, The Christie National Health Services Foundation Trust, Manchester, United Kingdom; Department of Medicine I, Medical University Vienna, Vienna, Austria
| | - D. R. Spigel
- Department of Clinical and Biological Sciences, University of Turin, S. Luigi Hospital, Turin, Italy; Sumy Regional Oncology Centre, Sumy, Ukraine; National Kyushu Cancer Center, Fukuoka, Japan; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; National Cancer Center, Tokyo, Japan; Department of Medical Oncology, The Christie National Health Services Foundation Trust, Manchester, United Kingdom; Department of Medicine I, Medical University Vienna, Vienna, Austria
| |
Collapse
|
41
|
Scagliotti G, Vynnychenko I, Ichinose Y, Park K, Kubota K, Blackhall FH, Pirker R, Galiulin R, Ciuleanu T, Sydorenko O, Dediu M, Papai-Szekely Z, Martinez Banaclocha N, McCoy S, Yao B, Hei YJ, Spigel DR. An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.lba7512] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
42
|
Treat J, Scagliotti G, Peng G, Monberg MJ, Obasaju CK. Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): A combined analysis of three phase III trials. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e18004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
43
|
Lara P, Douillard J, Nakagawa K, Von Pawel J, McKeage MJ, Albert I, Losonczy G, Reck M, Heo DS, Fan X, Fandi A, Scagliotti G. Randomized phase III placebo-controlled trial of carboplatin/paclitaxel (CP) with or without the vascular-disrupting agent vadimezan (ASA404) in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.7502] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
44
|
Sandler A, Schiller JH, Hirsh V, Sequist LV, Soria J, Von Pawel J, Wang Q, Pande AU, Schwartz BE, Garmey EG, Gorbatchevsky I, Scagliotti G. A phase III, randomized, double-blind, placebo-controlled study of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated subjects with locally advanced or metastatic, nonsquamous, non-small cell lung cancer (NSCLC) . J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.tps217] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
45
|
Vigano' MG, Cavina R, Novello S, Grossi F, Santoro A, Gregorc V, Scagliotti G, Garassino IM, Rossoni G, Levra MG, Genova C, Caligaris-Cappio F, Lambiase A, Bordignon C. Phase II trial of NGR-hTNF and doxorubicin in relapsed small cell lung cancer (SCLC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.7077] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
46
|
Novello S, Scagliotti G, Torri V, Monica V, Papotti M, Grohe C, Valmadre G, Bria E, Colantonio I, Serke MH, Stoelben E, Geissler M, Schena M, Santo A, Alabiso O, Schumann C, Manegold C. International tailored chemotherapy adjuvant trial: ITACA trial. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e17514] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
47
|
Gaafar RM, Surmont V, Scagliotti G, Van Klaveren R, Papamichael D, Welch J, Hasan B, Torri V, Van Meerbeeck JP. A double-blind, randomized, placebo-controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non-progressing after first-line platinum-based chemotherapy (EORTC 08021-ILCP 01/03). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.7518] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
48
|
Vadhan-Raj S, Henry DH, von Moos R, Hungria V, Goldwasser F, Scagliotti G, Wang J, Jun S, Dansey RD, Yeh H. Denosumab in the treatment of bone metastases from advanced cancer or multiple myeloma (MM): Analyses from a phase III randomized trial. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.9042] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
49
|
Novello S, Camps C, Grossi F, Mazieres J, Abrey LE, Vernejoux J, Thall AD, Usari T, Chao RC, Scagliotti G. Phase II study of sunitinib in patients with non-small cell lung cancer (NSCLC) and irradiated brain metastases: Final efficacy and safety results. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.7581] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
50
|
Blayney JK, Grills CM, Jithesh PV, Wistuba II, Jacobson M, O'Byrne KJ, Kerr KM, Scagliotti G, Holt RJ, Fennell DA. Evaluation of machine learning versus Cox regression in identification of factors predicting recurrence following resection of non-small cell lung cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.1599] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|